Nifty
:
24435.95
Sensex
:
77966.35
-35.75 (-0.15%)
-187.90 (-0.24%)
Nifty
Sensex
:
:
24435.95
77966.35
-35.75 (-0.15%)
-187.90 (-0.24%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
67/99

BSE: 539523 | NSE: ALKEM

NSE BSE
5480.00
12-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  5518
  •  5534.5
  •  5411.5
  •  5527.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  110443
  •  601685275.5
  •  5933.5
  •  5075

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 65,402.06
  • 28.41
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 65,292.65
  • 0.97%
  • 4.74

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.70%
  • 0.09%
  • 17.04%
  • FII
  • DII
  • Others
  • 10.41%
  • 20.84%
  • 1.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.97
  • 6.71
  • 5.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.60
  • 7.84
  • 5.92

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.95
  • 6.96
  • 8.66

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.54
  • 29.17
  • 29.52

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.87
  • 5.04
  • 5.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.13
  • 20.97
  • 21.49

Earnings Forecasts:

(Updated: 08-08-2026)
Description
2026
2027
2028
2029
Adj EPS
69
-6
4.01
209.39
P/E Ratio
79.42
-913.33
1366.58
26.17
Revenue
27.86
24.28
21.06
14596.3
EBITDA
16492.3
18273.3
20199.5
3021.35
Net Income
3411.52
3906.07
4433.39
2522.94
ROA
2412.97
2769.12
3273.24
13.71
P/B Ratio
-1.98
-1.39
-0.90
4.77
ROE
4.21
3.72
3.24
19.25
FCFF
16.05
16.33
15.86
1545.61
FCFF Yield
1744.75
2066.54
2254.58
2.35
Net Debt
2.65
3.14
3.42
-3084.3
BVPS
-2763.11
-3954.24
-6090.67
1149.18

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
3,603.32
3,143.75
14.62%
3,736.82
3,374.28
10.74%
4,000.99
3,414.67
17.17%
3,371.14
3,031.82
11.19%
Expenses
3,085.93
2,752.46
12.12%
2,908.82
2,614.89
11.24%
3,080.22
2,661.84
15.72%
2,632.09
2,423.18
8.62%
EBITDA
517.39
391.29
32.23%
828.00
759.39
9.03%
920.77
752.83
22.31%
739.05
608.64
21.43%
EBIDTM
14.36%
12.45%
22.16%
22.51%
23.01%
22.05%
21.92%
20.08%
Other Income
200.07
145.96
37.07%
143.10
92.99
53.89%
103.69
134.48
-22.90%
136.49
120.31
13.45%
Interest
53.88
28.42
89.58%
42.10
36.03
16.85%
35.02
28.14
24.45%
29.78
29.11
2.30%
Depreciation
105.76
112.49
-5.98%
95.01
85.28
11.41%
93.61
78.91
18.63%
87.68
80.48
8.95%
PBT
422.85
396.34
6.69%
781.20
731.07
6.86%
895.83
780.26
14.81%
771.01
619.36
24.48%
Tax
171.17
73.33
133.42%
127.67
90.28
41.42%
116.23
78.30
48.44%
102.69
69.12
48.57%
PAT
251.68
323.01
-22.08%
653.53
640.79
1.99%
779.60
701.96
11.06%
668.32
550.24
21.46%
PATM
6.98%
10.27%
17.49%
18.99%
19.49%
20.56%
19.82%
18.15%
EPS
19.78
25.58
-22.67%
53.20
52.35
1.62%
63.99
57.60
11.09%
55.56
45.60
21.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
-
14,712.27
12,964.52
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
Net Sales Growth
-
13.48%
2.34%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
 
Cost Of Goods Sold
-
4,546.79
4,121.25
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
Gross Profit
-
10,165.48
8,843.27
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
GP Margin
-
69.10%
68.21%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
Total Expenditure
-
11,717.97
10,452.37
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
Power & Fuel Cost
-
171.03
168.99
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
% Of Sales
-
1.16%
1.30%
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
Employee Cost
-
2,837.11
2,453.92
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
% Of Sales
-
19.28%
18.93%
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
Manufacturing Exp.
-
1,178.22
1,282.95
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
% Of Sales
-
8.01%
9.90%
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
General & Admin Exp.
-
1,114.27
850.62
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
% Of Sales
-
7.57%
6.56%
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
Selling & Distn. Exp.
-
1,550.12
1,319.76
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
% Of Sales
-
10.54%
10.18%
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
Miscellaneous Exp.
-
320.43
254.88
406.87
181.00
85.84
91.05
130.67
127.28
107.99
596.44
% Of Sales
-
2.18%
1.97%
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
EBITDA
-
2,994.30
2,512.15
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
EBITDA Margin
-
20.35%
19.38%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
Other Income
-
594.26
493.74
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
Interest
-
160.78
121.70
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
Depreciation
-
382.06
357.16
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
PBT
-
3,045.72
2,527.03
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
Tax
-
517.76
311.03
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
Tax Rate
-
18.03%
12.31%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
PAT
-
2,303.77
2,166.10
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
PAT before Minority Interest
-
2,353.13
2,216.00
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
Minority Interest
-
-49.36
-49.90
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
PAT Margin
-
15.66%
16.71%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
PAT Growth
-
6.36%
20.62%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
 
EPS
-
192.62
181.11
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
13,820.10
11,984.87
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
13,760.65
11,924.81
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
Non-Current Liabilities
-78.01
-447.74
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
Secured Loans
39.61
62.42
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
Unsecured Loans
452.84
248.49
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
Long Term Provisions
431.21
338.22
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
Current Liabilities
4,782.70
3,960.67
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
Trade Payables
2,244.18
1,937.35
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
Other Current Liabilities
1,186.08
1,068.22
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
Short Term Borrowings
1,085.25
734.89
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
Short Term Provisions
267.19
220.21
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
Total Liabilities
19,053.62
15,946.56
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
Net Block
3,871.03
2,852.31
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
Gross Block
6,069.65
4,719.78
4,543.69
4,050.24
4,185.64
3,723.05
3,606.95
3,026.08
2,603.78
1,977.20
Accumulated Depreciation
2,198.62
1,867.47
1,670.91
1,367.39
1,283.91
930.07
698.94
495.64
320.19
180.16
Non Current Assets
6,843.10
5,007.03
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
Capital Work in Progress
281.79
548.07
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
Non Current Investment
1,131.50
943.24
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
Long Term Loans & Adv.
363.58
277.96
203.74
139.07
154.44
93.77
90.65
111.47
133.68
185.16
Other Non Current Assets
1,195.20
385.45
78.60
274.70
697.18
48.55
54.19
53.82
100.11
413.74
Current Assets
12,210.52
10,811.19
10,411.58
8,606.42
8,433.70
6,923.27
5,487.57
4,204.40
4,013.22
2,915.32
Current Investments
737.31
902.26
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
Inventories
3,333.22
2,922.41
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
Sundry Debtors
2,979.11
2,466.25
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
Cash & Bank
1,732.90
1,563.08
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
Other Current Assets
3,427.98
156.28
237.13
244.68
825.68
834.34
757.29
566.64
567.93
302.86
Short Term Loans & Adv.
3,206.78
2,800.91
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
Net Current Assets
7,427.82
6,850.52
6,417.03
4,899.27
3,628.36
3,319.22
2,242.99
1,986.87
1,629.91
1,225.63
Total Assets
19,053.62
15,818.22
14,060.07
12,330.89
12,758.20
10,405.80
8,994.89
7,488.83
7,010.02
5,869.96

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
1,963.03
1,912.84
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
PBT
2,870.89
2,527.03
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
Adjustment
136.33
103.80
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
Changes in Working Capital
-415.17
-213.97
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
Cash after chg. in Working capital
2,592.05
2,416.86
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-629.02
-504.02
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,667.21
-1,298.76
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
Net Fixed Assets
-179.69
75.19
-74.10
-101.58
-278.91
-115.11
-310.63
-342.15
-531.27
-390.07
Net Investments
-1,145.15
-1,577.80
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
Others
-342.37
203.85
-1,110.97
691.36
-779.99
-687.09
-170.28
176.86
200.90
464.11
Cash from Financing Activity
-503.40
-810.99
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
Net Cash Inflow / Outflow
-207.58
-196.91
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
Opening Cash & Equivalents
-120.09
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
Closing Cash & Equivalent
-342.13
-120.09
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
1153.04
999.47
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
ROA
13.44%
14.77%
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
ROE
18.29%
19.93%
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
ROCE
21.28%
21.56%
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
Fixed Asset Turnover
4.18
4.17
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
Receivable days
44.04
44.62
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
Inventory Days
50.59
52.79
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
Payable days
167.84
163.20
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
Cash Conversion Cycle
-73.22
-65.80
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
Total Debt/Equity
0.12
0.09
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
Interest Cover
18.86
21.76
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Alkem Laboratories launches semaglutide in single-shot pre-filled syringes
    3rd Jun 2026, 09:50 AM

    The company is the first company in India to introduce semaglutide in single-shot pre-filled syringe format

    Read More
  • Alkem Laboratories - Quarterly Results
    29th May 2026, 00:00 AM

    Read More
  • Alkem Laboratories reports 23% fall in Q4 consolidated net profit
    28th May 2026, 18:06 PM

    Consolidated total income of the company increased by 15.61% at Rs 3,803.39 crore for Q4FY26

    Read More
  • USFDA completes inspection at Alkem Laboratories’ CRO facility in Taloja
    9th May 2026, 12:18 PM

    At the end of the inspection, no form 483 was issued

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.